The Pharma Data

JULY 22, 2021

This collaboration has the potential to be transformational, as it combines our leadership in targeted protein degradation with Pfizer’s global capabilities and deep expertise in breast cancer. The companies will equally share worldwide development costs, commercialization expenses, and profits. Terms of the Collaboration.

Targeted Protein Degradation 52

Targeted Protein Degradation Therapies Clinical Trials Treatment 52

Drug Target Review

JULY 5, 2024

The biosensor-OOC micro-engineered models can help elucidate the complexity of GBM by recapitulating brain tumour vasculature and replicating aspects of the tumour microenvironment, comprised of cell proliferation, migration and tangled cell interactions between tumour and endothelial cells. 15(9):700-706 (2018) [link] Deshmukh V, et al.

Targeted Protein Degradation 64

Targeted Protein Degradation Drugs Disease FDA Approval 64

LifeSciVC

OCTOBER 28, 2024

As context, biotech business models have largely had two flavors for decades: asset-centric investments focused on specific product opportunities and platforms (discovery engines) designed to create new drugs based on novel modalities, technologies, or biological insights. late 2015, late 2018).

Licensing 91

Licensing Licensing Marketing Targeted Protein Degradation 91